RecruitingPhase 2NCT06345495
High Dose Ruxolitinib and Allogeneic Stem Cell Transplantation in Myelofibrosis Patients With Splenomegaly
Sponsor
M.D. Anderson Cancer Center
Enrollment
30 participants
Start Date
Oct 1, 2024
Study Type
INTERVENTIONAL
Conditions
Summary
To learn if giving ruxolitinib and busulfan before a stem cell transplant can help to reduce spleen size and help the transplant to succeed.
Eligibility
Min Age: 18 YearsMax Age: 75 Years
Plain Language Summary
Simplified for easier understanding
This clinical trial is studying a procedure called Allogeneic Stem Cell Transplantation, a drug called Busulfan, and others for people with myelofibrosis and splenomegaly. The study is currently recruiting participants at 1 location. People eligible for this study include aged 18 Years to 75 Years.
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
DRUGRuxolitinib
Given by PO
PROCEDUREAllogeneic Stem Cell Transplantation
Given by Transplant
DRUGLevetiracetam
Given by PO
DRUGEltrombopag
Given by PO
DRUGBusulfan
Given by IV
DRUGRomiplostim
Given by IV
DRUGFludarabine phosphate
Given by IV
DRUGCyclophosphamide
Given by IV
DRUGMesna
Given by IV
DRUGTacrolimus
Given by IV or PO
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06345495
Related Trials
Study of DISC-0974 (RALLY-MF) in Participants With Myelofibrosis or Myelodysplastic Syndrome and Anemia
NCT0532019828 locations
Haplo-HSCT for Myelofibrosis
NCT066743821 location
A Telehealth Advance Care Planning Intervention
NCT058758051 location
A Study to Compare Elritercept to Placebo in Adults With Myelofibrosis and Anemia Who Are Taking Ruxolitinib
NCT07623161207 locations
A Study of Oral Nuvisertib (TP-3654) in Patients With Myelofibrosis
NCT0417619884 locations